METHODS Design
This study was a single-center, retrospective observational study. The Kobe University Hospital Ethics Committee approved this investigation. The committee waived the need for informed consent for studies involving the use of a database.
Setting and Participants
We screened patients over 20 years of age who had undergone CVS with CPB from January 2008 to December 2015 in our hospital. We excluded patients with missing data for perioperative serum creatinine (sCr) levels and relevant confounders, including those who died intraoperatively. We also excluded patients who required renal replacement therapy (RRT) preoperatively and patients who had descending aortic aneurysm replacement because of the presence of renal ischemia during surgery.
Anesthetic Management
All of the patients had general anesthesia. None of the patients received premedication. The protocol of anesthesia for CVS in our department is as follows. For induction of anesthesia, patients were anesthetized with 0.5-2 mg/kg of propofol and/or 1-5 mg of midazolam. Then the patients were intubated after administration of 0.6 mg/kg of rocuronium, 1-5 μg/kg of fentanyl, and/or 0.1-0.5 μg/kg/minute of remifentanil. For anesthetic maintenance, we gave sevoflurane or propofol, remifentanil, fentanyl, and rocuronium. During induction and maintenance, we tried to keep mean blood pressure at more than 65 mm Hg. During CPB, blood pressure was also maintained at more than 65 mm Hg.
Haptoglobin Administration
The attending certificated anesthesiologist decided whether to administer haptoglobin according to the presence of hemolytic urine. Clinically, the anesthesiologist considered the administration of haptoglobin by observing the phenomenon of the urinary color becoming red. Usually, 2000 units of haptoglobin was given. If hemolytic urine persisted, another 2000 units of haptoglobin was given. Medical insurance covers up to 4000 units of haptoglobin in this cohort. Information on the administration of haptoglobin was retrieved and was confirmed by the medical insurance claim.
Data Collection
We collected data from electronic medical records for patients' characteristics including age, sex, body weight, preoperative Hb level, preoperative estimated glomerular filtration rate (pre-eGFR), left ventricular fractional shortening (FS), European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), 13 presence of treated hypertension, diabetes mellitus, atrial fibrillation, previous history of CVS, and preoperative use of intra-aortic balloon pump (IABP). We also collected operative information such as type of surgery, operation time, duration of CPB, amount of intraoperative red blood cell (RBC) transfusion, and operators.
Outcomes
The primary outcome of this study was the incidence of pAKI that occurred within 48 hours after the operation. We used preoperative sCr as a baseline value and diagnosed pAKI using criteria of the AKI Network: (1) an absolute increase in sCr of 0.3 mg/dL or more; or (2) percentage increase in sCr of 50% or more (1.5-fold from baseline). 14 We also categorized patients who required postoperative renal replacement therapy within 48 hours after the operation as pAKI. The secondary outcome was maximal sCr for 48 hours after surgery. Measurement of sCr was routinely done before surgery, immediately after surgery, and in the mornings of postoperative days 1 and 2.
Statistical Analysis
The results are shown as median (25-75%, interquartile range [IQR]), n (%), or odds ratio (95% confidence interval [CI]). We divided the patients into 2 groups according to the administration of haptoglobin. Then, we compared those with and without haptoglobin administration using the Mann-Whitney U test or χ 2 test. Given the differences between the characteristics of patients with and those without haptoglobin administration, propensity score matching was used to identify a cohort of patients with similar characteristics. The propensity score in the current study was the probability of administration of intraoperative haptoglobin provided from a data set of covariates. As there was no study to identify the independent predictors of administration of haptoglobin, the propensity score was calculated by a logistic regression model with administration of haptoglobin as a dependent outcome. We used age, sex, weight, preoperative Hb, preeGFR, FS, EuroSCORE II, presence of chronic hypertension, presence of diabetes mellitus, presence of atrial fibrillation, history of previous CVS, preoperative use of an IABP, year of surgery, type of surgery, emergency operation, operation time, duration of CPB, amount of intraoperative RBC transfusion, and operators as covariates. Matching was conducted with 1:1 matching using nearest-neighbor matching without replacement, with a caliper width equal to 0.02 in propensity score units. We used a structured iterative approach to refine the logistic regression model in order to achieve a balance of covariates within the matched pairs. We used the standardized difference to measure covariate balance, with an absolute standardized difference above 0.1 representing meaningful imbalance. Then, we compared those with and without haptoglobin administration in matched cohort using the Mann-Whitney U test or χ 2 test. For sensitive analysis, we further developed a logistic regression model to estimate the independent association of the use of intraoperative haptoglobin with the risk of pAKI. Baseline characteristics related with the incidence of pAKI (P < .10) were chosen and added to the analysis in a stepwise manner.
We used SPSS 20.0 to perform statistical analysis. A P value <.05 was defined as a statistically significant difference. Data are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 15 
RESULTS

Study Flow
We screened 1740 consecutive patients who had cardiac surgery required CPB ( Figure) . We excluded 135 patients with missing data for perioperative sCr levels and 216 patients who had descending aorta replacement. We then excluded 50 patients who required renal replacement therapy preoperatively. After excluding 13 patients with missing information, we finally included 1326 patients in this study. pAKI occurred in 338 (25.5%) of the 1326 patients.
Haptoglobin Administration and Potential Confounders
Among the 1326 patients, there were 260 patients (19.6%) who were administered haptoglobin intraoperatively. There were 244 patients who received 2000 units of haptoglobin and 16 patients who received 4000 units. Table 1 shows a comparison of demographics for patients with and those without haptoglobin administration. In the crude cohort, patients with administration of haptoglobin had significantly higher body weight (P < .001), were more likely to have a higher preoperative Hb level (P < .001), lower preeGFR (P = .03), and premorbid atrial fibrillation (P < .001), were less likely to undergo an emergency operation (P = .003), had a longer duration of the operation (P < .001) and CPB (P < .001), and had a larger amount of RBC transfusion (P = .02) than those without administration of haptoglobin. There was also significant difference in operators between the 2 groups. There was no significant difference in age, sex, FS, EuroSCORE II, presence of hypertension and diabetes, previous history of CVS, preoperative use of an IABP, and surgery type between the 2 groups.
Primary and Secondary Outcomes in the Crude Cohort
In the crude cohort, the incidence of pAKI in patients with haptoglobin administration was 24.6% (64 of 260 patients), which was not significantly different from the incidence of 25.7% (274 of 1066 patients) in those without haptoglobin administration (P = .72; odds ratio, 0.94 [95% CI, 0.69-1.29]) ( Table 2 ). The maximal sCr was not significantly different between patients with and without haptoglobin administration (median of maximal sCr, 1.04 (IQR, 0.81-1.31) mg/dL vs 0.98 (0.77-1.34) mg/dL; P = .58).
Propensity-Matched Analysis
Since we found the significant heterogeneity between the patients with and those without haptoglobin administration, we conducted propensity score matching to adjust for the potentially confounding variables. After propensity score matching, we had selected 249 patients in each group. After propensity score matching, the standardized mean differences were less than 0.1 among all variables. Thus, the covariate balance in the matched cohort appeared to be considerably improved ( Table 1 ). The incidence of pAKI in patients with administration of haptoglobin was 22.5%, which was significantly lower than the incidence of 30.9% in those without haptoglobin administration (P = .033; odds ratio, 0.65 [0.43-0.97]) ( Table 2 ). The maximal sCr was significantly lower in patients with haptoglobin administration when compared with those without haptoglobin administration (median of maximal sCr, For sensitive analysis, we developed a logistic regression model for the risk of pAKI (Table 3) . In this analysis, haptoglobin administration was independently associated with decreased risk of pAKI (adjusted odds ratio, 0.54 [95% CI, 0.31, 0.93]; P = .029). In the propensity score matching analysis, intraoperative haptoglobin administration was significantly associated with decreased risk of pAKI after CVS. Although this is a hypothesis-generating retrospective study, our study is the first to show the potential of haptoglobin administration for prevention of pAKI in patients undergoing CVS. Thus, it might be relevant, and it requires further discussion.
Comparison With Previous Studies
There were 2 studies in which the impact of administration of haptoglobin on renal impairment was assessed. 11, 12 In a prospective observational study that included 14 patients who underwent cardiac surgery requiring CPB, haptoglobin was administered when fHb exceeded 30 mg/dL. The dose of haptoglobin was not shown in that report. N-acetyl-dglucosaminidase (NAG) level after haptoglobin administration was 43 mU/mg, which was significantly lower than the level of 169 mU/mg measured before its administration (P < .05). They also reported that α1-microglobulin level after haptoglobin administration was significantly lower than that before administration (104 vs 45 μg/mg; P < .01).
11
A small RCT was performed to assess the effect of intraoperative administration of haptoglobin. Adult patients scheduled to undergo open-heart surgery with CPB (n = 8 for the control group; n = 11 for the haptoglobin group) were included in that trial. For patients assigned to the haptoglobin group, 4000 units of haptoglobin was added to the priming solution of CPB. In the haptoglobin group, NAG at admission to the intensive care unit (ICU) was significantly lower than that in the control group (0.6 vs 2.5 U/L; P < .01). Urinary gammaglutamyltranspeptidase in the haptoglobin group at admission to the ICU was lower than that in the control group. 12 There has been no other study in which the effect of administration of haptoglobin on kidney impairment or function in patients undergoing CVS was assessed. In this regard, our findings are consistent with results of previous studies, but a novel finding regarding this issue has been added.
Interpretation
We found a significant association of haptoglobin administration with decreased incidence of pAKI. There are several possible explanations for this association. First, the decision to give haptoglobin was made by the physician in charge. Such a selection could bias our results and may not be able to adjust for using known confounders. However, the physicians used haptoglobin depending on urine color, not the patient's status. Therefore, bias is unlikely.
Second, haptoglobin administration might not have been used for patients with a small amount of intraoperative urine because urine color could not be recognized for such patients. Haptoglobin administration might also not have been used for patients with diluted urine. Since the amount of intraoperative urine might be associated with the incidence of pAKI, these facts may have skewed our results.
Third, haptoglobin administration might reduce the incidence of pAKI. 9 The use of CPB and a cell salvage system and the transfusion of stored RBCs cause the release of fHb into blood plasma. 6 If the concentration of serum Hp, which is a scavenger of fHb, is not sufficiently high, increased serum fHb may cause NO depletion, oxidant stress, and vascular dysfunction. 7 Additionally, methemoglobin generated from fHb may damage renal tubules. Furthermore, studies have indicated that uptake of the haptoglobin-Hb complex by macrophages may play a protective role against iron-induced tissue injury by upregulation of CD163 expression, secretion of the antiinflammatory cytokine IL-10, and upregulation of heme oxygenase-1 expression. 10, 16 These mechanisms may contribute to renal dysfunction that accompanies hemolysis. 8 Accordingly, some studies have shown a relationship between the presence of hemolysis during CVS with CPB and increased risk of pAKI. 17, 18 A previous study showed that administration of haptoglobin prevented AKI in cardiac surgery patients. 11, 12 Finally, there might be another unknown mechanism or any combination of the above mechanisms.
Limitations
This study has some limitations. First, this was an observational study in nature, and thus our findings showed an association but not a causality link. However, our study might have a potential to generate a hypothesis for establishing methods to prevent pAKI in this cohort.
Second, this was a small, single-center study with weak generalizability. Thus, our findings should be validated outside of study sites.
Third, as we did not have any information to estimate strength of association of haptoglobin with the risk of pAKI, we could not perform sample size calculation before conducting the current study. The study period was determined by the presence of a reliable data set; then, we included entire patients according to our inclusion criteria. Finally, as our study included 498 patients in this propensity-matching cohort (249 per cohort) with 30.9% incidence of pAKI in patients without haptoglobin administration, our study eventually has 80% power to detect the 11.3% difference of them with haptoglobin administration. Therefore, our study should be small with a chance of type I error. Thus, our findings should be confirmed or refuted by future studies.
Finally, there were no certain criteria for the administration of haptoglobin. Its administration was decided by the urinary color becoming red. Thus, mild hematuria might have been overlooked and would have skewed the results. In this regard, a future prospective study should be conducted with an established protocol for haptoglobin administration. 
